This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase 2 trial of AS902330 administered intra-articularly in subjects with primary osteoarthritis of the knee and Kellgren-Lawrence Grade 2 or 3. The trial is intended to investigate the efficacy and safety of different intra articular dosages of AS902330 (Sprifermin) in these individuals.